Gilead Sciences (NASDAQ:GILD) Rating Reaffirmed
This Morning, Wells Fargo has reaffirmed their Market Perform rating on Gilead Sciences (NASDAQ:GILD) shares in an analyst research report released.
From a total of 15 analysts covering Gilead Sciences (NASDAQ:GILD) stock, 14 rate it a ”Buy”, 1 a “Sell”, and 4 a ”Hold”. This means that 74% of the ratings are positive. The highest target price is $138 while the lowest target price is $102. The mean of all analyst targets is $125 with a 25.32% above today’s ($101.75) stock price. Gilead Sciences was the topic of 20 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Piper Jaffray upgraded shares on November 5 to “Overweight” rating. Needham maintained shares with “Buy” rating and $125 target share price in a report from a July 29. Oppenheimer maintained GILD stock in a recent report from October 20 with “Outperform” rating. RBC Capital Markets maintained the rating on July 29. RBC Capital Markets has a “Outperform” rating and a $130 price target on shares. Finally, Vetr upgraded the stock to “Buy” rating in a report issued on an August 17.
Approximately 13,311 shares of stock traded hands. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 3.46% since May 1, 2015 and is downtrending. It has underperformed by 0.67% the S&P500.
Gilead Sciences, Inc. , is a research biopharmaceutical firm that discovers, develops and commercializes innovative medicines. The company has a market cap of $146.11 billion. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. It has 9.29 P/E ratio. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta.
According to Zacks Investment Research, “Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.” Get a free copy of the Zacks research report on Gilead Sciences, Inc. (GILD).